http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1907375-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dee3727dba91e4e7aa3b26ce9efbcc21 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 |
| filingDate | 2006-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18c77e9ecfffca5abeda0d4297f6afd8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91adf0254e764777a36c8a334be51d39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6f138cf47b3e06fcbf9fc11d3995800 |
| publicationDate | 2008-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1907375-A2 |
| titleOfInvention | Crystalline solvate of omeprazole sodium |
| abstract | The present invention belongs to the field of pharmaceutical industry and relates to novel crystalline omeprazole sodium ethanol solvate and to the process for its preparation, which acts as intermediary compound to the processes for its conversion into different crystalline forms, first of all to a known omeprazole sodium form A, with low amount of residual solvents, i.e. less than 0.5% by weight of residual solvent. The present invention also relates to novel crystalline omeprazole sodium form E and crystalline omeprazole sodium form F as well to the processes for their preparation as well, both with considerably low levels of residual solvents. Omeprazole sodium form A and both novel crystalline forms omeprazole sodium form E and form F are useful for the treatment of gastrointestinal disorders. |
| priorityDate | 2005-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 85.